Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pharmacokinetic and local toxicity studies of liposome-encapsulated and plain mepivacaine solutions in rats

Full text
Author(s):
Show less -
Tofoli, Giovana Radomille [1, 2] ; Saia Cereda, Cintia Maria [1] ; de Araujo, Daniele Ribeiro [3, 1] ; de Paula, Eneida [1] ; Brito Junior, Rui Barbosa [4] ; Pedrazzoli Junior, Jose [2] ; Meurer, Eduardo [2] ; Proenca Barros, Fabio Alessandro ; Groppo, Francisco Carlos [5] ; Volpato, Maria Cristina [5] ; Ranali, Jose [5]
Total Authors: 11
Affiliation:
[1] Univ Estadual Campinas, Dept Biochem, Inst Biol, BR-13083970 Campinas, SP - Brazil
[2] Univ Sao Francisco, UNIFAG Clin Pharmacol & Gastroenterol Unit, BR-12900000 Braganca Paulista, SP - Brazil
[3] Fed Univ ABC, Human & Nat Sci Ctr, Santo Andre, SP - Brazil
[4] Sao Leopoldo Mand Dent Res Inst, Dept Mol Biol, Campinas, SP - Brazil
[5] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: DRUG DELIVERY; v. 17, n. 2, p. 68-76, FEB 2010.
Web of Science Citations: 6
Abstract

The pharmacokinetics and the local toxicity of commercial and liposome-encapsulated mepivacaine formulations injected intra-orally in rats were studied. Animals were divided in groups (n=4-6) and treated with 0.1 mL of the formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC(2%EPI)), 3% mepivacaine (MVC(3%)), and 2% liposome-encapsulated mepivacaine (MVC(LUV)). The results showed that the 2% liposome-encapsulated mepivacaine reduced C(max), prolonged AUC(0-infinity) and t(1/2) compared with 3% plain and 2% vasoconstritor-associated mepivacaine, after intraoral injection. In addition, it was also observed that liposomal mepivacaine might protect the tissue against local inflammation evoked by plain or vasoconstrictors-associated mepivacaine, giving supporting evidence for its safety and possible clinical use in dentistry. (AU)

FAPESP's process: 06/00121-9 - New formulations for the controlled release of local anesthetics in dentistry: from development to clinical tests
Grantee:Eneida de Paula
Support Opportunities: Research Projects - Thematic Grants